Gilead (GILD) Announces European CHMP Adopts Positive Opinion for Aztreonam Lysine
More News related to GILD
- Gilead Sciences to Present at the 18th Annual Credit Suisse Healthcare Conference on Wednesday, November 11
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Gilead Sciences (GILD) and Glaxo (GSK) Announce Pulmonary Arterial Hypertension Clinical Trial
- Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
- Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating Viread(R) For Chronic Hepatitis B
More News related to Corporate News
- After-Hours Movers 11/09: SGK, PCLN, SQNM Higher; MBI, SDTH, UTK, TOPS, CPST, BTN, FLR Lower
- Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
- Unusual 11 Mid-Day Movers 11/09: EONC, EWBC, REV, PRST Higher; GTN, CHNG, SRZ, CHDX Lower
- Notable Analyst Rating Changes: RSH, ANF, NOC, ADBE, HERO Upgraded; RIMM, RHT, GPS, AZN, SGY Downgraded
- Morning Movers 11/09: EWBC, CVM, REV, CGEN, RSH Higher; CHDX, SRZ, GTN, RPRX, VSR Lower
Gilead Sciences, Inc. (Nasdaq: GILD) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing Authorisation Application for aztreonam lysine 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 18 years and older. The opinion is for conditional approval, contingent on the successful completion of an ongoing study.
The CHMP's positive recommendation will be reviewed by the European Commission, which has the authority to approve medicinal products for use in the 27 countries of the European Union. Gilead expects the European Commission to issue its decision on the marketing authorization for aztreonam lysine later this year. Aztreonam lysine was previously reviewed by the CHMP in March and received a negative opinion, which Gilead appealed.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.32Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
